MDACC Study No:2011-0254 ( NCT No: NCT01460498)
Title:Phase I-II Study of Low-Dose Azacitidine (Vidaza) in Patients With Chronic Myeloid Leukemia who Have Minimal Residual Disease While Receiving Therapy with Tyrosine Kinase Inhibitors (VZ-CML-PI-0236)
Principal Investigator:Jorge Cortes
Treatment Agent:Azacitidine
Study Status:Closed
Study Description:This is a 2 part study. The goal of the first part of this clinical research
study is to find the highest tolerable dose of azacitidine that can be given
with a TKI that you are already taking (such as Gleevec, Sprycel, or Tasigna).
The safety of this drug will also be studied. The goal of the second part is to
see if this combination may improve your response to the TKI you are already

Azacitidine is designed to change genes that are thought to cause leukemia. By
changing these genes, the drug may help to stop them from causing the disease
to grow.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Azacitidine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Celgene Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults